Purpose Despite widespread use of fluorouracil, epirubicin, cyclophosphamide, docetaxel (FEC-D) chemotherapy in breast cancer, the optimal strategy for primary febrile neutropenia (FN) prophylaxis remains unknown. A systematic review was therefore performed.

Methods Embase, Ovid MEDLINE, PubMed, Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, and conference proceedings were searched from 1946 to April 2016 for trials that reported the effectiveness of primary FN prophylaxis with FEC-D chemotherapy. Outcome measures were incidence of FN; treatment-related hospitalizations; chemotherapy dose delays, reductions, and discontinuations; and adverse events from prophylaxis.

Results Of 2,205 identified citations, eight studies (n = 1,250) met our eligibility criteria. Three additional studies (n = 293) were identified from a prior systematic review. Three randomized controlled trials (n = 576), one phase IV single-arm trial (n = 69), one prospective observational study (n = 37), and six retrospective studies (n = 861) were identified. Agents investigated were pegfilgrastim (n = 108), filgrastim (n = 1,119), and ciprofloxacin (n = 89). The heterogeneity of studies meant that a narrative synthesis of results was performed. Median FN rates for patients who received FEC-D with and without primary prophylaxis were 10.1% (interquartile range [IQR], 3.9% to 22.6%) and 23.9% (IQR, 9.2% to 27.3%), respectively. In the absence of primary prophylaxis, FN was more common during docetaxel than during FEC. Data from six studies showed a median rate of dose reductions and delays of 6.1% (IQR, 3.1% to 14.3%) and 19.3% (IQR, 10.5% to 32.8%), respectively, that occurred as a consequence of FN. Toxicity from prophylaxis itself was rarely reported.

Conclusion Primary FN prophylaxis is effective in patients who receive FEC-D chemotherapy. The paucity of prospective data makes optimal recommendations about the choice and timing of prophylaxis challenging.
FN prophylaxis should be recommended with FEC-D chemotherapy, no consensus has been reached on the optimal strategy (ie, either G-CSF or oral antibiotics) or timing (ie, from the start of chemotherapy or during the docetaxel component only) of such prophylaxis. These limitations are important given the considerable differences in cost and toxicity between agents.

To our knowledge, no high-quality evidence guides optimal FN prophylaxis with this commonly used chemotherapy regimen. Hence, we performed a systematic review to evaluate the incidence of FN with FEC-D (with and without primary prophylaxis), its timing, and optimal strategies for primary FN prophylaxis. We also identified gaps in the available literature that require further study.

METHODS

Study Objective and Eligibility Criteria
This systematic review was performed to identify and evaluate the incidence and timing of FN in the absence of primary FN prophylaxis and the effects of two strategies (G-CSF and antibiotics) for primary FN prophylaxis in patients who received six to eight cycles of FEC-D chemotherapy once every 3 weeks for early-stage breast cancer. The population, intervention, comparator, and outcome study design framework was used to structure the research question and its corresponding literature search. The population of interest was patients with breast cancer who received FEC-D chemotherapy in the adjuvant or neoadjuvant setting. Interventions of interest were primary FN prophylaxis G-CSF (ie, filgrastim, pegfilgrastim, biosimilars) and prophylactic antibiotics of any treatment duration. Primary FN prophylaxis was defined as prophylactic administration of hematopoietic cell growth factors (eg, G-CSF) or quinolone antibiotics to prevent the occurrence of infection. Comparators were best supportive care or prophylactic quinolone antibiotics. The primary outcome measure was the incidence of FN (defined as an absolute neutrophil count < 0.5 × 10⁹/L with oral temperature > 38.3°C or a temperature of > 38.0°C sustained over a 1-hour period). Secondary outcome measures were treatment-related hospitalizations; chemotherapeutic dose reductions, delays, and discontinuations; and frequency of adverse events from primary FN prophylaxis. Interventional or retrospective and prospective observational studies published in English were included. Animal studies, studies in the metastatic setting, and studies that involved patients who had received prior chemotherapy and secondary FN prophylaxis were excluded.

Literature Search
An information specialist (R.S.) designed and executed an electronic literature search to identify relevant citations from Embase, Ovid MEDLINE, PubMed (including in-process and other nonindexed citations), the Cochrane Database of Systematic Reviews, the Cochrane Register of Controlled Trials, and conference proceedings from 1946 to April 26, 2016. Search terms and their medical subject heading equivalents are shown in the Data Supplement.

Study Screening and Selection
Stage 1 screening consisted of a review of titles and abstracts identified from the literature search by two independent reviewers (R.F. and S.M.). Disagreements between the reviewers were discussed and resolved. A third reviewer was consulted if necessary to achieve consensus. Stage 2 screening consisted of a full-text review of all manuscripts and meeting abstracts from potentially relevant citations identified during stage 1 screening by two independent reviewers (R.F., S.M., C.S., M.F.K.I., S.D., K.P., L.V., or M.C.). We also reviewed the relevant studies included in a previous systematic review.8 The screening process is presented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Fig 1), and a PRISMA checklist was completed to document reporting elements of the review17 (Data Supplement).

Data Collection and Risk of Bias Assessment
Data from the final set of included studies were extracted by two reviewers independently who used a predesigned form implemented in Microsoft Excel version 2010 (Microsoft Corporation, Redmond, WA); discrepancies were resolved by consensus discussion. The following information was collected from each study: publication characteristics (year, journal, and authors), patient characteristics (performance status, median age, and disease stage), intervention characteristics (chemotherapy regimen, neoadjuvant or adjuvant setting, type and frequency of G-CSF, and antibiotics used), and outcomes of interest (the incidence of febrile neutropenia; hospitalizations; chemotherapeutic dose reductions, delays, and discontinuations; and frequency of adverse events from primary FN prophylaxis). Authors were contacted to acquire
other unpublished data. The Cochrane Collaboration’s tool for assessing risk of bias in randomized controlled trials was used (Data Supplement). Funding for the current study was from internal sources, and there was no pharmaceutical company funding.

Data Analysis

If deemed appropriate, after exploration of study and patient characteristics to ensure sufficient clinical and methodological homogeneity across studies, we had planned to conduct meta-analyses using random-effects models to combine FN incidence data across studies. After inspection of the characteristics of the included studies, the research team determined a high degree of study heterogeneity in terms of study populations and design. We believed that these differences precluded the data from meta-analysis. To synthesize the information collected, a narrative summary was prepared to document incidence of FN and to summarize other related information, such as hospitalizations, the consequence of FN on chemotherapy, and adverse events.

RESULTS

Quantity of Evidence Identified

From 2,205 unique citations identified by the literature search, 77 potentially relevant studies were identified during the stage 1 screening of titles and abstracts. These 77 studies were subsequently reviewed in full text for stage 2 screening; eight of these studies met the eligibility criteria. In addition, three studies identified from a prior systematic review were included (Table 1). Reasons for study exclusion during stage 2 screening were absence of FEC-D chemotherapy use (n = 32), lack of individual results on patient population with breast cancer (n = 8), systematic review/review article (n = 5), absence of FN data (n = 3), metastatic breast cancer (n = 3), economic analysis (n = 2), multiple chemotherapy regimens used (n = 2), secondary FN prophylaxis (n = 2), no G-CSF or antibiotics interventions (n = 1), duplicate publication (n = 1), and non-breast cancer study (n = 1). Of the 11 included studies, eight were available as peer-reviewed manuscripts and three were available as meeting abstracts.

---

### Table 1: Reasons for Study Exclusion

| Reason                                      | Number |
|---------------------------------------------|--------|
| Absence of FEC-D chemotherapy               | 32     |
| Lack of individual results on patient population with breast cancer | 8      |
| Systematic review/review article            | 5      |
| Absence of FN data                          | 3      |
| Metastatic breast cancer                    | 3      |
| Economic analysis                           | 2      |
| Multiple chemotherapy regimens used         | 2      |
| Secondary FN prophylaxis                    | 2      |
| No G-CSF or antibiotics interventions       | 1      |
| Duplicate publication                       | 1      |
| Non-breast cancer study                     | 1      |

---

Record screened in full text (n = 77)

| Excluded Reason                                      | Number |
|------------------------------------------------------|--------|
| Absence of FEC-D chemotherapy                        | 32     |
| Lack of individual results on patient population      | 8      |
| Systematic review/review article                     | 5      |
| Absence of FN data                                   | 3      |
| Metastatic breast cancer                              | 3      |
| Economic analysis                                     | 2      |
| Multiple chemotherapy regimens used                  | 2      |
| Secondary FN prophylaxis                              | 2      |
| No G-CSF or antibiotics interventions                 | 1      |
| Duplicate publication                                 | 1      |
| Non-breast cancer study                               | 1      |

Records identified and screened through database and abstract search after removal of duplicates (n = 2,205)

Records excluded because of irrelevancy (n = 2,128)

Studies included in qualitative synthesis (n = 11)

---

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. FEC-D, fluorouracil, epirubicin, cyclophosphamide, docetaxel; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor.
were published in 1998,23 2003,22 2008,24 2009,21
2010,19,20,25 2011,26 2012,18 2013,17 and 2015.16

Study Characteristics

Eligible studies included three randomized trials (n = 576), one phase IV single-arm trial (n = 69),
one prospective observational study (n = 37), and
six retrospective observational studies (n = 861).
Sample sizes ranged from 3219 to 44822 patients.
Pegfilgrastim was evaluated in two studies (n = 108),20,21
dafilgrastim in seven (n = 1,119),16,17,22-26
and ciprofloxacin in one (n = 89).23 None of the
included studies reported use of interim neutrophil
counts to guide G-CSF dosing.

Characteristics of the individual studies (study
design; sample size; breast cancer stage; hormonal
status; type of intervention; incidence of FN with
and without primary prophylaxis; number of cycles
delivered; number of patients and cycles with FN;
incidence of hospitalizations; chemotherapy-adequate
dose reductions, delays, and discontinuation;
and frequency of adverse events) are listed in
Table 1. As a result of considerable variability
between studies in terms of study design and
evaluated outcomes, meta-analysis was consid-
ered inappropriate, and a narrative summary as
well as a descriptive overview of common results
are presented. For example, few studies reported
medical comorbidities, such as vascular disease,
diabetes, and chronic obstructive pulmonary dis-
ease, known to affect FN rates.20

FN Rates and Primary FN Prophylaxis

Overall, we found 1,543 patients treated with FEC-D
(median age, 54 years; range, 24 to 78 years). FEC-D chemotherapy
with and without primary prophylaxis was associated
with median FN rates of 10.05% (range, 0.2% to 25%) and 23.9%
(range, 5% to 27.7%), respectively.

With respect to each primary prophylaxis treat-
ment, pegfilgrastim was used as a primary pro-
phylaxis in two prospective studies.20,21 One study
showed that among 32 patients treated with FEC-D
who received primary FN prophylaxis with pegfil-
grastim, FN developed in 5%.21 The other trial
demonstrated that 9% of the 69 patients treated
with FEC-D experienced FN despite receipt of
primary prophylaxis with pegfilgrastim.20 Two
studies provided detailed information about the
use of primary prophylactic filgrastim.16,17 One
trial demonstrated that 9% of the 69 patients treated
with FEC-D experienced FN despite receipt of
primary prophylaxis with pegfilgrastim.20 Two
studies provided detailed information about the
use of primary prophylactic filgrastim.16,17 One
trial demonstrated that 100 patients treated with
FEC-D, 26% and 10% had FN without and with
filgrastim prophylaxis, respectively.17 In the other
study, with a cohort of 189 patients treated with
FEC-D, filgrastim was used in 1.8% and 9% during
the FEC and docetaxel phases, respectively.16

Timing of FN

Four studies reported the differences in FN rates
between the FEC and docetaxel phases. In one
study where 189 patients were treated with FEC-D,
7% and 21% experienced FN during the FEC and
docetaxel phases, respectively.16 In another trial

| First Author | Study Design | Sample Size | Median Age | G-CSF PP, % | Incidence of FN With PP, % | Incidence of FN Without PP, % | Hospitalizations From FN, % of Total Courses | Dose Reduction After FN, % | Dose Delay After FN, % |
|--------------|--------------|-------------|------------|--------------|----------------------------|-----------------------------|---------------------------------|-------------------------|------------------------|
| Miguel       | Retrospective | 189         | 61         | 1.80         | 0.20                       | 3                           | 42.90                           | 7.10                    | 28.6                   |
| Al Zaman     | Retrospective | 100         | 54         | 31           | 10                         | 26                          | 30                              | 17.0                    | 10.0                   |
| Cousin       | Retrospective | 284         | 49         | 0            | No PP                      | 5                           | 1                               | 1.00                    | 34.2                   |
| Caley        | Retrospective | 32          | NR         | 0            | No PP                      | 21.8                        | NR                              | NR                      | NR                     |
| Rader        | Open-label phase IV | 69          | 54         | 100          | 9                         | NR                          | 0.01                           | NR                      | NR                     |
| Wildiers     | Randomized phase II | 39          | 48         | 100          | 5                         | NR                          | NR                              | 5.10                    | 0                      |
| Therasse     | Randomized phase III | 448         | 49         | NR           | NR                        | NR                          | NR                              | NR                      | NR                     |
| Bergh        | Randomized    | 89          | NR         | 100          | NR                        | NR                          | NR                              | NR                      | NR                     |
| Head         | Retrospective study | 137        | NR         | 21           | 25                        | NR                          | NR                              | NR                      | NR                     |
| Tran         | Retrospective | 119         | NR         | 78.20        | 21.8                      | NR                          | NR                              | NR                      | NR                     |
| Rayson       | Prospective observational | 37          | 54         | 16           | 0                         | 27.70                       | NR                              | NR                      | NR                     |

Abbreviations: FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; NR, not reported; PP, primary prophylaxis.
of 284 patients who had FEC-D without primary prophylaxis, 14 (4.9%) had FN. Overall, FN developed in 2.1% of patients during FEC cycles, whereas FN related to docetaxel occurred in 1.4% of patients.18 The third study comprised 32 patients treated with FEC-D without primary prophylaxis, where 9% and 21.8% experienced FN during the FEC and docetaxel phases, respectively.19 Finally, Rayson et al26 showed that among 37 patients without primary FN prophylaxis, the FEC and docetaxel cycles were associated with 35% and 62% FN rates, respectively. In summary, primary prophylaxis was only used in 9% to 24% of patients, and most episodes of FN occurred during docetaxel administration (interquartile range [IQR], 6.3% to 51.95%; median, 21.4%). In contrast, in the absence of primary prophylaxis, a median of 8% (IQR, 3.25% to 28.5%) of patients experienced FN during FEC cycles.16,18,19,26

Risk Factors for FN

Traditional risk factors with a high/intermediate level of supporting evidence for FN are extensive prior chemotherapy; > 85% relative intensity; age older than 65 years; poor performance status; low albumin/high lactate dehydrogenase levels; comorbidities such as pulmonary, cardiovascular, and liver disease; and diabetes mellitus.9-12 Primary prophylaxis was not used in all the included studies (median, 36.9%; range, 0% to 100%). FN risk factors were identified in two studies.16,20 In these two studies, the percentage of patients older than 65 years were 33.3%16 and 19%.20 Furthermore, 17% of patients were found to have medical comorbidities, such as vascular disease, diabetes, and chronic obstructive pulmonary disease.20 In one of the two studies that reported FN rates according to a 65-year age cutoff, the risk of developing FN during FEC was equal in patients older and younger than 65 years (risk ratio, 1.05; 95% CI, 0.51 to 2.2).16

Consequences of FN

Data from six studies reported a median number of dose reductions and delays of 6.1% (IQR, 3.05% to 14.25%) and 19.3% (IQR, 10.5% to 32.8%) as a consequence of FN.16-20,22 Hospital admission as a result of FN occurred in 0.04% to 33.4% (median, 3%) of cases. The median duration of hospitalization reported was 6 days (range, 2 to 13 days).16-18,20 Only one study reported chemotherapy discontinuation rates as a result of FN that occurred in 6.7% of patients.18 Of note, across all the studies, no deaths occurred as a result of FN.

Toxicity of Primary FN Prophylaxis

Few studies reported adverse effects of primary prophylaxis. Two studies with filgrastim reported primary prophylaxis toxicity, such as back pain (0.4%) and Clostridium difficile infection (7.6%).17,20

DISCUSSION

FN is an important toxicity associated with FEC-D chemotherapy and can be associated with significant morbidity, mortality, and costs as well as a result of chemotherapy dose reductions, delays, and discontinuations. Because the proportion of FN cases in the absence of primary prophylaxis exceeds 20% with FEC-D chemotherapy, most guidelines9-13 recommend the use of primary FN prophylaxis. Primary prophylaxis is usually in the form of G-CSF or antibiotic use. However, despite the considerable differences in the cost and toxicity profiles of these agents as well as significant differences in the risk of FN depending on the chemotherapy received (docetaxel > FEC), we were unaware of high-quality data that compared either the choice of agent or its timing (during administration of FEC, docetaxel, or both).

The most effective strategy of providing FN prophylaxis is an important question not only to the physician and patients but also to the entire health care system in both the developed and the developing world because of its financial implications. Given the greater drug cost of pegfilgrastim over filgrastim, most health care funders will cover filgrastim, even though some data suggest that pegfilgrastim is superior and more cost-effective than filgrastim (Clinical Trials Information: NCT02173262).27,28 From a cost perspective alone, the cost differences are important from a global health care standpoint, with three cycles of FEC-D being associated with direct drug costs of $CAD1,740 for filgrastim for 10 days and $CAD2,422 for pegfilgrastim and $CAD35 for ciprofloxacin for 14 days.9 These costs do not include the charges for a health care professional to administer the G-CSF injections. Furthermore, from clinical experience, FN is much more commonly observed during the docetaxel component of treatment than during the FEC cycles. Finally, the toxicities of G-CSF differ from those of antibiotics as well as differ according to duration of use. Possible adverse effects of ciprofloxacin are nausea (> 2%) and, less commonly, diarrhea.
and vomiting (< 1%). Possible adverse effects of G-CSF (> 10%) are bone pain, headaches, irritation at the injection site, and diarrhea. The current systematic review attempts to address these questions from the synthesis of available evidence.

To our knowledge, this systematic review is the second to evaluate G-CSF and antibiotic use in patients with breast cancer who underwent FEC-D chemotherapy. Overall, median FN rates for patients who receive FEC-D with and without primary prophylaxis are 10.05% (IQR, 3.8% to 22.6%) and 23.9% (IQR, 9.2% to 27.2%), respectively. With respect to the timing of FN, four studies showed that most episodes occurred during docetaxel infusion cycles (median, 21.4; IQR, 6.3 to 51.9) compared with during FEC cycles (median, 8%; IQR, 3.3% to 28.5%). With respect to the choice of primary prophylaxis, pegfilgrastim (n = 108), filgrastim (n = 1,119), and ciprofloxacin (n = 89) were used. However, variable reporting of the use of different agents at different times (during FEC, docetaxel, or both) and as primary or secondary FN prophylaxis made it challenging to identify the optimal strategy. In fact, none of the included studies compared both strategies.

This systematic review had limitations. First, the included studies were mostly retrospective in design. Second, and of note, despite the widespread global use of FEC-D for more than a decade, a paucity of high-quality literature on the incidence, measurement, treatment, and prophylaxis of FN exists. The identified studies also lacked detailed and consistent outcome data, two of which were published in abstract form only, which leads to a risk of bias in these trials. Finally, although we aimed to compare two FN primary prophylaxis options (G-CSF and antibiotics), we were unable to find any such trial conducted previously.

Future studies are needed to determine the most effective treatment strategies to provide appropriate patient selection and individualized drug dosing and to prevent and reduce treatment-related toxicities. Only one clinical trial prospectively looked at optimal duration of filgrastim as FN primary prophylaxis, specifically in patients with early-stage breast cancer who underwent commonly used adjuvant chemotherapy regimens, including FEC-D. Unfortunately, no definitive results were available for antibiotic use. In addition, future trials could assess the timing of primary FN prophylaxis, for example, either from the start of FEC-D treatment or during the docetaxel component only. Robust economic analyses also are needed.

In conclusion, FN is a common toxicity of FEC-D chemotherapy. In light of the 20% FN threshold currently recommended for primary prophylaxis, the current results suggest that primary prophylaxis should be considered for the FEC-D regimen in routine clinical practice. Large population-based studies will help to clarify FN incidence in the real world, and randomized clinical trials are crucial to the establishment of treatment strategies and improvement of optimal G-CSF use.

DOI: 10.1200/JGO.2016.008540
Published online on jgo.org on April 21, 2017.

AUTHOR CONTRIBUTIONS
Conception and design: Ricardo Fernandes, Sasha Mazzarello, Habeeb Majeed, Risa Shorr, Brian Hutton, Dean Fergusson, Mark Clemons
Collection and assembly of data: Ricardo Fernandes, Sasha Mazzarello, Carol Stober, Mohamed F.K. Ibrahim, Shaan Dudani, Kirstin Perdrizet, Habeeb Majeed, Lisa Vandermeer, Bishal Gyawali, Mark Clemons
Data analysis and interpretation: Ricardo Fernandes, Brian Hutton, Dean Fergusson, Mark Clemons
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

Ricardo Fernandes
No relationship to disclose
Sasha Mazzarello
No relationship to disclose
Carol Stober
No relationship to disclose
Mohamed F.K. Ibrahim
No relationship to disclose
Shaan Dudani
No relationship to disclose
Kirstin Perdrizet
No relationship to disclose
Habeeb Majeed
No relationship to disclose
Lisa Vandermeer
No relationship to disclose

For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Ricardo Fernandes
No relationship to disclose
Sasha Mazzarello
No relationship to disclose
Carol Stober
No relationship to disclose
Mohamed F.K. Ibrahim
No relationship to disclose
Shaan Dudani
No relationship to disclose
Kirstin Perdrizet
No relationship to disclose
Habeeb Majeed
No relationship to disclose
Lisa Vandermeer
No relationship to disclose
REFERENCES

1. Fisher B, Jeong JH, Dignam J, et al: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001:62-66, 2001

2. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Breast cancer. V2.2013. http://www.nccn.org

3. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006

4. Culakova E, Thota R, Poniewierski MS, et al: Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study. Cancer Med 3:434-444, 2014

5. Lathia N, Mittmann N, DeAngelis C, et al: Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742-748, 2010

6. Dinan MA, Hirsch BR, Lyman GH: Management of chemotherapy-induced neutropenia: Measuring quality, cost, and value. J Natl Compr Canc Netw 13:1-e7, 2015

7. Rayson D, Lutes S, Sellon M, et al: Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: A prospective study. Curr Oncol 19:e216-e218, 2012

8. Younis T, Rayson D, Thompson K: Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: A systematic review and meta-analysis. Support Care Cancer 20:2523-2530, 2012

9. Cancer Care Ontario: Cancer Care Ontario GCSF recommendations 2016. https://www.cancercare.on.ca/common/pages/UserFile.aspx?field=352101

10. Reference deleted.

11. Crawford J, Allen J, Armitage J, et al: NCCN clinical practice guidelines in oncology (NCCN Guidelines) myeloid growth factors. Version 1.2012. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

12. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32, 2011

13. Thomas J, Bohlke K, Lyman GH, et al: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199-3212, 2015

14. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London, UK, The Cochrane Collaboration, 2011

15. Skoetz N, Bohlius J, Engert A, et al: Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. Cochrane Database Syst Rev 12:CD007107, 2015

16. Miguel I, Winckler P, Sousa M, et al: Febrile neutropenia in FEC-D regimen for early stage breast cancer: Is there a place for G-CSF primary prophylaxis? Breast Dis 35:167-171, 2015

17. Reference deleted.

18. Cousin S, Le Rhun E, Mailliez A, et al: Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. Bull Cancer 99:75-80, 2012

19. Caley A, Bertelli G, Rolles M, et al: Adjuvant taxane chemotherapy is associated with a significant risk of febrile neutropenia. Eur J Cancer 8:70, 2010 (abstr 40)
20. Rader M, Breyer W, Luedke S, et al: Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices. Community Oncol 7:273-280, 2010

21. Wildiers H, Dirix L, Neven P, et al: Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114:103-112, 2009

22. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003

23. Bergh J, Wiklund T, Erikstein B, et al: Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Ann Oncol 9:403-411, 1998

24. Head J, Archer C, Harper-Wynne C, et al: Rates of neutropaenic sepsis with the use of adjuvant FEC100-docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; a UK perspective. NCRI Cancer Conference, Birmingham, UK, October 5-8, 2008 (abstr B64)

25. Tran M, Simmons CE, Haq R, et al: A pragmatic review of adjuvant chemotherapy regimens in early-stage breast cancer—hematologic toxicities experienced in a single institution. Cancer Res 70, 2010 (abstr P5-10-24)

26. Rayson D, Lutes S, Sellon M, et al: (2011) Population-based incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: A prospective study. St Gallen Breast Cancer Conference, St Gallen, Switzerland, March 16-19, 2011 (abstr P332)

27. Naeim A, Henk HJ, Becker L, et al: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: A retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11, 2013

28. Liu Z, Doan QV, Malin J, et al: The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 7:193-205, 2009

29. Bayer Inc: Product monograph: PrCipro XL (ciprofloxacin hydrochloride and ciprofloxacin extended release tablets), 2015. http://www.bayer.ca/omr/online/cipro-xl-pm-eng-9mar2015.pdf

30. Amgen Canada Inc: Product monograph: PrNeupogen (filgrastim), 2015. https://www.amgen.ca/Neupogen_PM.pdf